Diabetic-Friendly Drug-Eluting Stent System to Debut in India

Published date : 02 October 2012
Article date : 02 October 2012

Massdevice reports that Medtronic's Resolute Integrity stent is to make its market debut in India, following FDA clearance, in February.

They say that the device is the first of its kind approved for use in patients with diabetes in addition to coronary artery disease (CAD). With India hosting the 2nd largest population of diabetics in the world, the launch may be an important one for patients in the country as well as for the manufacturer's ongoing commitment to expanding the company's reach in emerging markets. 

According to the Medtronic, CAD patients with diabetes represent a difficult-to-treat population, as they often have smaller and more complex arteries, longer lesions and a higher rate of treatment failures. Apparently, because of complications arising from the co-morbidity, many patients are treated with open heart surgery, a more invasive option that requires extended hospital care and recovery time. 

Although percutaneous interventions are often used for diabetic patients with CAD, no drug-eluting stent had previously been approved specifically for that population. 

Source: Massdevice, 28 September 2012

Read the full article here

Back to Listings

WhichMedicalDevice is a FREE resource created by clinicians for clinicians.

Registration is free and gives you unlimited access to all of the content and features of this website.

Find out more...

Please sign in to view this content...

I have forgotten my password
Not a Member?

Registration is free and gives you unlimited access to all of the content and features of Which Medical Device. Find out more...

Why Register

Which Medical Device is a community of clinicians sharing knowledge and experience of the devices and procedures we use on a daily basis. We ask that our members register with us so that we can maintain the unbiased and independent nature of our content. Registration is quick and free.

We do not make your details available to any third parties nor do we send unsolicited emails to our members. You can read our Privacy Policy here.